Core Viewpoint - The company has signed a licensing and commercialization agreement with STADA for BAT1806 (Tocilizumab) injection, granting STADA exclusive commercialization rights in several regions, which is expected to positively impact the company's future performance [1][2][3] Agreement Summary - The agreement allows STADA to commercialize BAT1806 in the EU, Switzerland, the UK, parts of Europe, the MENA region, and CIS countries [1][2] - The total transaction amount can reach up to €136 million, including an upfront payment of €8.5 million and milestone payments not exceeding €127.5 million, along with a double-digit percentage of net sales as revenue sharing [2][6] - The agreement will be effective upon approval by the company's shareholders and will last for an initial period of 15 years, automatically extending for 2 years unless either party provides written notice to terminate [2][6] Product and Partner Information - BAT1806 is a biosimilar developed according to guidelines from NMPA, FDA, and EMA, targeting the IL-6 receptor [3] - STADA is a well-established European pharmaceutical company with a focus on consumer health, generics, and specialty pharmaceuticals, achieving €4.059 billion in sales and €886 million in adjusted EBITDA in the 2024 fiscal year [3] Impact on Company Performance - The agreement is expected to enhance the company's global commercialization and profitability, leveraging STADA's strengths in research, production quality control, and market promotion [6][7] - The successful execution of this agreement is anticipated to have a positive impact on the company's future operating performance [6][7]